A Phase 2 interventional study of P03277 and Gadobenate dimeglumine in CNS Lesion and Blood Brain Barrier Defect, sponsored by Guerbet. Completed at 28 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-25.
Sponsored by Guerbet · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at 0.1 mmol/kg body weight (BW).
Contrast to Noise Ratio (CNR), a well-known quantitative parameter directly related to contrast medium/GBCA efficacy, was chosen as the primary endpoint in order to have a precise determination of P03277 clinical dose.
This was a multi-center, international, prospective, double-blind, randomized, controlled, parallel dose groups, cross-over with comparator study in male and female subjects presenting with known or highly suspected focal areas of disruption of the Blood Brain Barrier including at least one expected enhancing lesion of minimum 5 mm, who were scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System.
Two subsets of subjects were included in the study:
During the course of the study, two MRIs were obtained from each subject: one unenhanced and P03277-enhanced MRI; and one unenhanced and gadobenate dimeglumine-enhanced MRI. MRI images were evaluated off-site by 3 independent blinded readers for the primary endpoint (CNR).
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI
Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI
One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI
Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
Drug: P03277 · Drug: Gadobenate dimeglumine · Device: MRI
Single intravenous (IV) bolus injection at a rate of 2 mL/second
Also known as: Gadopiclenol
Single IV bolus injection at a rate of 2 mL/second
Also known as: MultiHance
Contrast to Noise Ratio (CNR) Difference
The Contrast-to-Noise Ratio (CNR) was calculated from the signal intensity measurement of maximum 3 enhanced lesions by 3 independent blinded readers. Only lesions detected by both MRIs after lesion tracking were used. The difference in CNR was calculated as follow: CNR (P03277) - CNR (gadobenate dimeglumine).
Time frame: 1 day procedure
| Milestone | Subset 1 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.025 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.2 mmol/kg/Gadobenate Dimeglumine |
|---|---|---|---|---|---|---|
| Started | 14 | 14 | 62 | 63 | 64 | 63 |
| Completed | 12 | 11 | 55 | 59 | 53 | 48 |
| Not completed | 2 | 3 | 7 | 4 | 11 | 15 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 2 | 1 | 3 |
| Withdrew: Various other reasons | 0 | 2 | 4 | 1 | 7 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 0 |
The Contrast-to-Noise Ratio (CNR) was calculated from the signal intensity measurement of maximum 3 enhanced lesions by 3 independent blinded readers. Only lesions detected by both MRIs after lesion tracking were used. The difference in CNR was calculated as follow: CNR (P03277) - CNR (gadobenate dimeglumine).
| Ratio | P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 1 | P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 1 | P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 1 | P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 1 | P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 2 | P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 2 | P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 2 | P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 2 | P03277 0.025 mmol/kg - Gadobenate Dimeglumine - Reader 3 | P03277 0.05 mmol/kg - Gadobenate Dimeglumine - Reader 3 | P03277 0.1 mmol/kg - Gadobenate Dimeglumine - Reader 3 | P03277 0.2 mmol/kg - Gadobenate Dimeglumine - Reader 3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contrast to Noise Ratio (CNR) Difference | -10.59 (-14.59 to -6.58) | 2.18 (-2.67 to 7.03) | 8.66 (3.52 to 13.79) | 14.45 (7.64 to 21.25) | -14.14 (-23.33 to -4.95) | 1.91 (-7.28 to 11.10) | 19.38 (11.42 to 27.34) | 38.37 (18.62 to 58.12) | -23.96 (-33.78 to -14.13) | 2.47 (-8.39 to 13.32) | 29.23 (16.05 to 42.41) | 51.96 (30.36 to 73.55) |
Collected over Adverse events were recorded from informed consent signature up to one day after the second MRI, up to 22 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| P03277 0.025 mmol/kg | 0/56 (0%) | 0/56 (0%) | 14/56 (25%) |
| P03277 0.05 mmol/kg | 0/74 (0%) | 0/74 (0%) | 12/74 (16.2%) |
| P03277 0.1 mmol/kg | 0/70 (0%) | 1/70 (1.4%) | 19/70 (27.1%) |
| P03277 0.2 mmol/kg | 0/56 (0%) | 1/56 (1.8%) | 18/56 (32.1%) |
| Gadobenate Dimeglumine | 0/256 (0%) | 2/256 (0.8%) | 57/256 (22.3%) |
| Event | P03277 0.025 mmol/kg | P03277 0.05 mmol/kg | P03277 0.1 mmol/kg | P03277 0.2 mmol/kg | Gadobenate Dimeglumine |
|---|---|---|---|---|---|
| Femoral neck fractureInjury, poisoning and procedural complications | 0/56 | 0/74 | 0/70 | 1/56 | 0/256 |
| Blood creatinine increasedInvestigations | 0/56 | 0/74 | 1/70 | 0/56 | 0/256 |
| SeizureNervous system disorders | 0/56 | 0/74 | 0/70 | 0/56 | 1/256 |
| Meningioma surgerySurgical and medical procedures | 0/56 | 0/74 | 0/70 | 0/56 | 1/256 |
| Event | P03277 0.025 mmol/kg | P03277 0.05 mmol/kg | P03277 0.1 mmol/kg | P03277 0.2 mmol/kg | Gadobenate Dimeglumine |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/56 | 2/74 | 5/70 | 7/56 | 9/256 |
| HeadacheNervous system disorders | 4/56 | 3/74 | 1/70 | 0/56 | 7/256 |
| Urinary tract infectionInfections and infestations | 1/56 | 1/74 | 3/70 | 1/56 | 4/256 |
| FatigueGeneral disorders | 2/56 | 0/74 | 0/70 | 2/56 | 1/256 |
| Injection site haematomaGeneral disorders | 0/56 | 0/74 | 0/70 | 2/56 | 0/256 |
| Blood pressure increasedInvestigations | 2/56 | 0/74 | 1/70 | 0/56 | 2/256 |
| DizinessNervous system disorders | 0/56 | 0/74 | 0/70 | 2/56 | 4/256 |
| NauseaGastrointestinal disorders | 0/56 | 0/74 | 0/70 | 1/56 | 9/256 |
| Electrocardiogram QT prolongedInvestigations | 0/56 | 0/74 | 2/70 | 0/56 | 0/256 |
| LeukocyturiaRenal and urinary disorders | 1/56 | 2/74 | 1/70 | 1/56 | 5/256 |
Subjects of subset 1 were only included in the safety assessment. The Full Analysis Set included 240 subjects from subset 2 who had available results for CNR from both unenhanced and enhanced measurements derivable from one MRI by at least one off-site reader. Analyses using the FAS were based on the contrast agent allocated by the randomization.
| Age, Continuous(years) | Subset 2 - P03277 0.025 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.2 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Total |
|---|---|---|---|---|---|---|---|
| Mean | 54.8 ± 10.9 | 54.0 ± 14.8 | 54.2 ± 14.4 | 52.1 ± 13.7 | 54.9 ± 13.3 | 56.1 ± 16 | 53.8 ± 13.5 |
| Sex: Female, Male(Participants) | Subset 2 - P03277 0.025 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.2 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Total |
|---|---|---|---|---|---|---|---|
| Female | 34 | 39 | 30 | 39 | 10 | 5 | 157 |
| Male | 23 | 23 | 31 | 21 | 4 | 9 | 111 |
| Race (NIH/OMB)(Participants) | Subset 2 - P03277 0.025 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Subset 2 - P03277 0.2 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.05 mmol/kg/Gadobenate Dimeglumine | Subset 1 - P03277 0.1 mmol/kg/Gadobenate Dimeglumine | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 8 | 5 | 8 | 4 | 2 | 1 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 4 | 2 | 2 | 2 | 12 |
| White | 47 | 55 | 49 | 54 | 10 | 11 | 226 |
| More than one race | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Jan 2018, 19 months.
Results were first posted in May 2019, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol